I/We claim:

1. A cannabinoid composition, comprising: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol ~~ranges from~~is between 1:1 ~~to~~ and 1:10~~, or from 1: 0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:0.7 to 1:1~~ and is not 1:1.

2. The cannabinoid composition according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol ~~ranges from~~is between 1:1 ~~to~~ and 1:3, or from 1:3 to 1:5, or from 1:5 to 1:7.

3. The cannabinoid composition according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is 1:3.

4. The cannabinoid composition according to claim 1, wherein the cannabinoid composition further comprises cannabinol.

5. The cannabinoid composition according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

6. The cannabinoid composition according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

7. The cannabinoid composition according to claim 4, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.

8. ~~An application of t~~The cannabinoid composition according to any of claims 1 to 7 ~~in preparing a medicine for treating~~ for use in the treatment of neurodegenerative diseases.

9. The cannabinoid composition ~~The application~~ according to claim 8, wherein the neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies.

~~10. The application according to claim 8, wherein the cannabinoid composition is applied to promote development and maturity of dopaminergic neuronal cells, prevent shedding of the dopaminergic neuronal cells, and enhance viability of the dopaminergic neuronal cells.~~

~~11. The application according to claim 8, wherein the cannabinoid composition is applied to enhance dopamine-secreting capability of dopaminergic neuronal cells.~~

~~12~~10. A pharmaceutical composition for use in the treatment of ~~treating~~ neurodegenerative diseases, wherein the pharmaceutical composition comprising: the cannabinoid composition according to any of claims 1 to 7, and a pharmaceutically acceptable carrier.

~~13~~11. The pharmaceutical composition according to claim ~~12~~10, wherein a dosage form of the pharmaceutical composition includes: oil agent, granule, tablet, pulvis, capsule, pill, powder, oral liquid, gel, spray, and aerosol.

~~14~~12. A pharmaceutical kit for use in the treatment of ~~treating~~ neurodegenerative diseases, the pharmaceutical kit comprising: the cannabinoid composition according to any of claims 1 to 7.